Diminished Circulating Monocytes after Peripheral Bypass Surgery for Critical Limb Ischemia by Magri, Dania
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library School of Medicine
5-6-2009
Diminished Circulating Monocytes after Peripheral
Bypass Surgery for Critical Limb Ischemia
Dania Magri
Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation
Magri, Dania, "Diminished Circulating Monocytes after Peripheral Bypass Surgery for Critical Limb Ischemia" (2009). Yale Medicine







Diminished Circulating Monocytes after Peripheral Bypass Surgery for 





A thesis submitted to the 
Yale University School of Medicine 
In partial fulfillment of the requirements for the  
Degree of Doctor of Medicine 










Introduction:   
Mononuclear cells (MNCs) have been shown to increase neovascularization and ulcer 
healing after direct injection into the ischemic limbs of patients with unreconstructable 
peripheral vascular disease (PVD). Circulating MNCs are composed of lymphocytes (85%), 
monocytes (15%) and endothelial progenitor cells (EPCs; 0.03%). It is thought that MNCs 
may be effective in ameliorating ischemia since EPCs are a component of the monocyte 
fraction, and EPCs have been shown to participate in vascular healing.  
 
We hypothesized that ischemic areas secrete paracrine signals such as cytokines and growth 
factors that recruit bone marrow-derived monocytes into the circulation in order to augment 
vascular healing. For this reason we predicted that patients with critical limb ischemia (CLI) 
undergoing bypass surgery would have elevated preoperative monocyte counts compared to 
control subjects without CLI. In addition, since a successful surgical bypass procedure 
relieves ischemia, we expected a postoperative decrease in circulating monocyte numbers. 
 
Methods:   
We reviewed the records of all patients at the VA Connecticut Healthcare System undergoing 
lower extremity peripheral bypass surgery between 2002 and 2007. Patients were excluded if 
they did not have both preoperative and postoperative complete blood counts with 
differentials within a given time frame. Subjects were divided into two groups: those with 
preoperative critical limb ischemia (CLI) and those without.  ANOVA and Chi-Square were 
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used to compare counts, and multivariable logistic regression was used to determine risk 
factors.  
 
Results:   
Patients with CLI (n=24) had elevated preoperative monocyte counts compared to control 
patients (n=8) undergoing bypass for claudication or asymptomatic popliteal aneurysm 
(0.753 ± 0.04 vs. 0.516 ± 0.05; p=0.0046), but the preoperative lymphocyte count was not 
significantly different (1.979 ± 0.14 vs. 1.912 ± 0.22; p=0.814).  After revascularization, 
ischemic patients had decreased monocyte counts compared to control patients (-20% vs. 
+55%; p=.0003) although lymphocyte ratios were unchanged in both groups (-10% vs. +1%; 
p=0.404). Diabetic patients also had reduced postoperative monocyte counts (-32% vs. 
+13%; p=0.035), however multivariable analysis demonstrated that the only factor that 
independently predicted reduced postoperative monocyte count was preoperative critical 
limb ischemia (p=0.038). 
 
Conclusions:  
Diminished numbers of circulating monocytes correlate with relief of ischemia after surgical 
revascularization.  Circulating monocytes may be a clinically useful surrogate marker of 
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Introduction and Background: 
 
The introduction is divided into two chapters.  The first chapter focuses on endothelial 
progenitor cells (EPCs), the newly described bone marrow-derived stem cells for the vascular 
system.  The second chapter introduces peripheral vascular disease (PVD), and further 
describes the relevance of EPCs and mononuclear cells (MNCs) in the context of patients 
requiring lower extremity bypass surgery for critical limb ischemia (CLI). Monocytes are 
then introduced as a potential clinically-relevant surrogate marker for circulating EPCs. 
 
Chapter I:  Endothelial Progenitor Cells (EPCs) 
 
EPC Significance: 
EPCs have been shown to participate in vascular healing during both acute injury and chronic 
disease. The quantity and quality of circulating EPCs correlate inversely with the severity of 
vascular disease; a reduction in number or function of EPCs are significant independent risk 
factors for an impaired healing capacity, a dysfunctional endothelium, and progression of 
atherosclerosis and vascular disease. EPC therapy has been shown to assist in healing of 
cardiac and limb ischemia; this therapy has great potential for improving the quality of life 
and longevity of patients with severe cardiovascular and peripheral vascular disease (PVD) 
who are not candidates for conventional revascularization procedures. In addition, EPCs can 
be used to promote vascular graft patency. This chapter focuses on the characterization of 
EPCs, positive and negative regulators of EPCs, the role of EPCs in vascular disease, and the 




Introduction to EPCs: 
The ability of endothelium to repair itself depends on recruitment, proliferation, and 
migration of surrounding mature endothelial cells as well as the mobilization and 
incorporation of circulating EPCs to the injured region. Recent studies have outlined the 
importance of EPCs with respect to atherosclerotic vascular disease, acute vessel injury, and 
tissue ischemia. EPCs are thought to promote healing of the endothelial monolayer and 
vessel wall primarily through processes of reendothelialization and neovascularization; these 
repair mechanisms have been shown to reduce the risk of atherosclerotic disease progression 
and minimize the negative sequelae of vessel wall injury and tissue ischemia.  
 
Risk factors such as elevated cholesterol, hypertension, diabetes, smoking, physical inactivity 
and advanced age are associated with chronic damage to the endothelial monolayer [1].  In 
addition, vessel trauma or ischemia can acutely compromise the integrity of the endothelium 
and result in endothelial cell apoptosis [2]. Vascular damage is repaired by two synergistic 
mechanisms, mediated by two different cell populations. Repair by local proliferation and 
migration of resident mature endothelial cells can repopulate the endothelial layer, but these 
cells have a limited capacity for regeneration; they become senescent and insufficient for 
proper healing as successive replications result in telomere shortening. Alternatively, 
circulating bone-marrow derived EPCs have been shown to migrate towards sites of injury 
and ischemia, proliferate, differentiate, and incorporate into injured vessel walls as well as 
generate new vessels. This repair mechanism provides a source of healthy endothelium with 




However, EPCs are also susceptible to senescence and dysfunction; normal aging in the 
presence of risk factors for vascular disease can lead to the progressive depletion of marrow 
cells that give rise to progenitors necessary for arterial repair [1,3]. EPC obsolescence 
implies insufficient circulating number and/or functional capacity of EPCs, and consequently 
a potential inability to maintain vascular integrity. In the setting of significant risk factors and 
a dysfunctional endothelium, which has a limited capacity to heal acute vessel injury, 
compensate for chronic vascular damage, and limit abnormalities in vasoreactivity, 
atherosclerotic disease will progress [3]. 
 
Pathophysiology of Atherosclerosis: 
Endothelial damage results in the release of chemokines and cytokines which initiate the 
inflammatory cascade. Some of these paracrine factors promote mobilization of EPCs from 
the bone marrow, migration to the peripheral circulation, and homing to sites of injury or 
ischemia. This activity is coordinated by complex interactions involving: VEGF (vascular 
endothelial growth factor), a growth factor that responds to tissue ischemia, assists in the 
recruitment of EPC, promotes new vessel formation, and is correlated with rapid EPC 
mobilization after traumatic vascular injury [4]; G-CSF (granulocyte colony stimulating 
factor), a growth factor for neutrophils that also mobilizes EPCs from the bone marrow; 
MMP-9 (matrix metalloproteinase-9), a type 4 collagenase and gelatinase that cleaves the 
extracellular matrix to allow EPC migration; and SDF-1 (stromal cell-derived factor-1), a 




Under circumstances where a competent bone marrow is able to produce a sufficient quantity 
of functional EPCs, these cells arrive at the site of injury and proliferate, differentiate, and 
incorporate into the vessel wall. Vascular healing occurs via reendothelialization and 
neovascularization, and with healing, the local inflammatory response resolves. A negative 
feedback loop results in termination of cytokine release in the absence of inflammation [1]. 
 
If the bone marrow is not competent and produces an insufficient quantity of functional EPCs 
in response to the local inflammation at the site of vascular damage, then healing does not 
occur. This may result from ineffective recruitment or impaired function of senescent EPCs.  
In this setting cytokines continue to be released by local inflammatory cells, causing further 
inflammation and tissue damage via a positive feedback loop. The failure of aging organisms 
to renew endothelial cells exposed to noxious stimuli leads to endothelial dysfunction, 
inflammation, and atherosclerosis [1,3]. 
 
EPC Number is Inversely Correlated with Vascular Disease Severity: 
Atherosclerosis is the result of chronic chemical or mechanical stresses that cause vascular 
damage in the setting of deficient repair mechanisms. It has been shown that the number of 
circulating EPCs is a significant independent predictor for the severity of atherosclerosis. Hill 
and colleagues measured the number of circulating EPCs in 45 men with a mean age of 50 
years having various degrees of cardiovascular risk but no history of cardiovascular disease. 
Endothelium-dependent and endothelium-independent vascular function was assessed by 
ultrasonography of the brachial artery. Interestingly, the researchers observed a strong 
inverse correlation between the number of circulating EPCs and the combined Framingham 
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risk score, which predicts a subject’s risk for cardiovascular disease. They also observed a 
significant positive correlation between the number of circulating EPCs and brachial artery 
endothelial function [5]. 
 
Werner and colleagues determined the number of EPCs in 519 patients with 
angiographically-proven coronary artery disease (CAD) and evaluated the association 
between baseline levels of EPCs and major cardiovascular events after 12 months. After 
adjustment for relevant variables, increased levels of EPCs were associated with a reduced 
risk of death from cardiovascular causes (hazard ratio 0.31), a first major cardiovascular 
event (hazard ratio 0.74), revascularization (hazard ratio 0.77), and hospitalization (hazard 
ratio 0.76) [6]. Thus these researchers showed that reduced levels of EPCs were a significant, 
independent predictor of poor prognosis even after adjustment for traditional cardiovascular 
risk factors and disease activity [7]. 
 
Characterization of EPCs: Lineage, Markers, and Abundance: 
EPCs are rare bone marrow-derived mononuclear cells (MNCs) that are enriched in the bone 
marrow, but may also be found in the mononuclear cell fraction of peripheral blood. These 
cells were first isolated and induced to differentiate into endothelial cells in vitro by Asahara 
and colleagues in 1997 [8,9].  Asahara and colleagues also noted the capacity for these cells 
to contribute to vasculogenesis as well as angiogenesis in the setting of tissue ischemia. 
[10,11]. However, many aspects of EPC characterization are currently debated, including 




During embryonic development the mesodermal layer develops into bone marrow and 
resident stem cells, including hematopoietic and mesenchymal stem cells. It is likely that 
EPCs are derived from hemangioblasts, the multipotent stem cells that are a common 
precursor to hematopoietic stem cells and EPCs; however, EPCs may also be derived directly 
from hematopoietic stem cells [12-14].  Alternatively, there is evidence to show that myeloid 
cells, which are bone marrow-derived hematopoietic committed progenitor cells, may 
transdifferentiate into EPCs [15]. This proposed lineage is shown in Figure 1. 
 
In addition, several other non-hematopoietic stem cell types have been induced to 
differentiate into mature endothelial cells. For example, multipotent adult progenitor cells 
isolated with mesenchymal stem cells and lacking hematopoietic stem cell markers can be 
cultured with VEGF and induced to differentiate into an endothelial phenotype that expresses 
endothelial cell markers, functions as a mature endothelial cell in vitro, and contributes to 
both wound healing and tumor angiogenesis in vivo [16]. 
 
Tissue-resident stem cells may also give rise to endothelial cells under certain conditions. For 
example, adult cardiac stem cells have been induced to differentiate into vascular tissues 
including vascular smooth muscle cells and endothelial cells. In one important study, 
Beltrami and colleagues demonstrated that an injection of clonally expanded tissue-resident 
cardiac stem cells into an ischemic heart resulted in regeneration of well-differentiated 
myocardium including new vessels and myocytes with the characteristics of young cells [17]. 
 
Side population (SP) cells, a heterogeneous cell population identified by a capacity to efflux 
13 
 
Hoechst-33342 and Rhodamine-123 dyes, are composed of hematopoietic stem cells and 
non-hematopoietic organ-specific multipotent stem cells [18].  SP stem cells are able to 
acquire the endothelial cell phenotype with VEGF stimulation, or acquire the smooth muscle 
cell phenotype with TGF-β1/PDGF-BB stimulation; in addition, SP cells can form branching 
vascular-like structures with evidence of both cell types in vitro [19]. Figure 1 shows several 
proposed routes for the derivation of endothelial cells from EPCs and other sources. 
 
EPCs have also been defined by their functional capacity to form endothelial cell colonies in 
vitro, incorporate acetylated low-density lipoprotein (LDL), and exhibit enhanced endothelial 
nitric oxide synthase (eNOS) expression after shear stress exposure [20,21]. 
 
EPCs can be further characterized using cell surface markers, as depicted in Figure 1. Most 
researchers agree that EPCs express the following markers: CD34, which is present on EPCs, 
certain hematopoietic cells, and endothelial cells; vascular endothelial growth factor receptor 
2 (VEGF-R2), which is essential for angiogenesis and vasculogenesis in conjunction with its 
ligand VEGF; and CD133, which is present on a variety of stem cells. It should be noted that 
EPCs in the bone marrow and early circulating EPCs express CD133, but after differentiation 
occurs circulating EPCs lose CD133 and gain several other surface markers, including 
platelet endothelial cell adhesion molecule (CD31), vascular endothelial cadherin (VE 
cadherin) and von Willebrand factor (vWF) [2,22].  
 
Another important cell surface marker is CXCR4, which is the receptor for stromal cell-
derived factor 1 (SDF-1). In the setting of tissue hypoxia, SDF-1 is upregulated by hypoxia 
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inducible factor-1 (HIF-1). The CXCR4/SDF-1 pair is known to be important in 
hematopoietic stem cell trafficking, including quiescence, homing to the bone marrow, and 
mobilization to sites of vascular injury and ischemia [23]. Of note, interfering with this 
receptor-ligand interaction can mobilize hematopoietic stem cells into the circulation by 
disrupting the CXCR4/SDF-1 bond that tethers these cells to the bone marrow.  
 
CD133 and CD34 are often used as markers for selection and purification of EPCs since 
CD133 is not found on mature endothelial cells, and CD34 is not found on the 
undifferentiated stem cells from which EPCs derive [24].  However, there is significant 
overlap in terms of cell surface markers. For example, mature endothelial cells which are 
shed from the vessel wall may express VEGF-R2, VE cadherin, and CD34. In addition, 
certain hematopoietic stem cells may express CD34, CD31, VEGF-R2, and vWF [13]. 
CD133 is found on bone marrow EPCs and early circulating EPCs, but once in the 
circulation, EPCs lose expression of CD133 and gain expression of other less specific cell 
surface markers as described above; the specificity of this marker is further compromised 
because hematopoietic progenitor cells may also express CD133 [2,25]. 
 
The lack of a specific marker that is present on all EPCs implies a technical challenge with 
respect to isolating these cells from peripheral blood, and has hampered the development of 
an established protocol for isolating these cells. Lack of a specific marker has been cited as a 
potential source for conflicting evidence in studies evaluating EPC number [1].  In addition, 
the possibility that there may be subpopulations of EPCs having different functional 
characteristics and surface markers adds to the complexity of the issue [26]. One 
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consequence of this problem is that many of the clinical studies evaluating the therapeutic 
effects of EPCs have been performed using bone marrow samples that have not been purified 
to exclude other cell types, leading to the possibility that the functional effects ascribed to 
EPCs may not be due to these cells alone [13]. 
 
Another confounding factor is that other cell types bearing different cell surface markers and 
derived from bone marrow, peripheral blood, or other tissues may be precursors to 
endothelial cells, making the “true” EPC more elusive. As described above, this is further 
complicated by the fact that other stem cell types may be induced to transdifferentiate into 
EPCs, including mesenchymal stem cells as well as the SP phenotype of human stem cells 
(Figure 1) [9,13]. 
 
During steady-state conditions in healthy patients, circulating EPCs comprise approximately 
0.01% of peripheral blood cells [13].  It has been repeatedly demonstrated that patients with 
chronic vascular disease have even fewer circulating EPCs. The rarity of this cell population 
is another factor that makes identification and isolation of these cells for therapy or for 
research very challenging.  
 
Regulators of EPC Number and Function: 
There are many positive and negative regulators of EPCs. These factors have a quantifiable 






Heiss and colleagues evaluated circulating EPC number and function, as well as endothelial 
function in 20 aged and young subjects with no major cardiovascular risk factors. They 
reported that while older people had impaired endothelial function, there was no significant 
difference in the number of circulating EPCs between the two age groups. However, EPCs 
from older people had significantly decreased survival, migration, and proliferation rates, 
suggesting that the impaired maintenance of the endothelium in older subjects may correlate 
with functional EPC deficits rather than total EPC number [27,28]. 
 
Normal aging diminishes the potential for mature endothelial cells to participate in effective 
vascular repair, resulting in progression of atherosclerosis. Impaired endothelial cell function, 
bone marrow senescence, and limited availability or compromised function of circulating 




Hypercholesterolemia is a significant risk factor for atherosclerosis. Rauscher and colleagues 
performed an elegant study demonstrating that long-term treatment with bone marrow-
derived progenitor cells from young non-atherosclerotic ApoE-deficient mice was successful 
in preventing atherosclerosis progression in ApoE-deficient recipients despite persistent 
hypercholesterolemia. In contrast, treatment with bone marrow cells from older ApoE-
deficient mice with atherosclerosis was much less effective. This study demonstrates the role 
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of competent EPCs in preventing atherosclerosis, as well as the decreased effectiveness of 
senescent EPCs to engraft on recipient arteries in areas at risk for atherosclerotic injury [3]. 
 
Diabetes  
Fadini and colleagues analyzed the association between type 2 diabetes, peripheral vascular 
disease (PVD), and levels of circulating EPCs. These researchers used flow cytometry to 
quantify circulating progenitor cells (CD34-positive) and EPCs (CD34-positive and VEGF-
R2-positive) in 51 diabetic patients and 17 control subjects. They reported that the number of 
circulating progenitor cells and EPCs from diabetic patients were reduced by 33% and 40%, 
respectively, compared with healthy subjects. An inverse correlation was found between the 
number of EPCs and the values of fasting glucose. In addition, they determined that PVD 
was associated with a 47% reduction in circulating EPCs, and that EPC number directly 
correlated with the ankle-brachial index [29]. 
 
In a second study, Fadini and colleagues quantified EPCs by flow cytometry in 127 diabetic 
patients with and without peripheral arterial disease (PAD). Diabetic patients with PAD 
displayed a 53% reduction in circulating EPCs compared to non-PAD patients, and EPC 
levels were negatively correlated with the degree of carotid stenosis and claudication 
symptoms. In addition, the proliferative and adhesion capacity of cultured EPCs were 
significantly lower in diabetic patients with PAD versus patients without PAD [30]. 
 
Tepper and colleagues expanded on these findings and noted that proliferation of diabetic 
EPCs relative to control subjects was decreased by 48% (p<0.01) and inversely correlated 
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with patient levels of hemoglobin A1c (p<0.05). In addition, diabetic EPCs demonstrated 
decreased adherence and were 2.5 times less likely to participate in tubule formation 
compared with controls (p<0.05) [31]. 
 
Smoking 
Kondo and colleagues examined the effects of chronic smoking and smoking cessation on 
EPC levels. Circulating EPCs were quantified by flow cytometry in 14 nonsmokers and 15 
smokers. The number of circulating EPCs was reduced in chronic smokers and inversely 
correlated with the number of cigarettes smoked. Circulating EPCs increased rapidly after 
smoking cessation (p<0.0001) and decreased again after resumption of smoking to a level 
similar to that before cessation (p=0.0031), suggesting that EPC levels directly respond to the 
effects of smoking [32]. 
 
Michaud and colleagues studied peripheral blood EPCs in 15 healthy smokers and 11 age-
matched nonsmokers. The number of EPCs was significantly reduced in smokers versus 
control subjects, and the functional activities of EPCs isolated from smokers were severely 
compromised. The proliferative response was reduced by 75% and the migratory response 
was reduced by 19% (p<0.05). EPCs from smokers also showed decreased adherence and 
diminished capacity to form tubes in a matrigel assay. These researchers also found that 
EPCs from smokers had a significant reduction in the expression of the endothelial cell-




Positive Regulators:  
Exercise 
It is generally accepted that exercise and physical training decrease the risk and severity of 
cardiovascular and peripheral vascular disease, but the molecular mechanisms for this 
protective effect have been elusive. Laufs and colleagues studied EPCs in mice randomized 
to either running wheels or no exercise. Numbers of EPCs circulating in the peripheral blood 
of trained mice were enhanced to 267%, 289%, and 280% of control levels after 7, 14, and 
28 days, respectively. The researchers identified an exercise-induced nitric oxide-dependent 
mechanism which elevated serum levels of VEGF and reduced the rate of apoptosis in 
spleen-derived EPCs. In addition, running inhibited neointima formation after carotid artery 
injury by 22% and increased neoangiogenesis by 41% compared with control animals [34]. 
 
Steiner and colleagues examined the effect of exercise on circulating EPCs in patients with 
cardiovascular risk factors and/or coronary artery disease (CAD). Twenty patients with 
documented CAD and/or cardiovascular risk factors joined a 12-week supervised running 
program. After 12 weeks of exercise there was a significant 2.9-fold increase in circulating 
EPCs, which was positively correlated with both the change in flow-mediated vessel dilation 
and the increase in nitric oxide synthesis. Interestingly, plasma VEGF levels did not change 
in response to exercise [35]. Thus regular exercise training appears to augment the number of 
circulating EPCs in patients with cardiovascular risk factors. 
 
Another study by Sandri and colleagues showed that ischemic exercise training in patients 
with PAD increased VEGF levels by 310% and the number of EPCs by 440% compared to 
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controls. However, subischemic exercise training in patients with PAD or CAD did not 
increase VEGF levels or EPC number, but was associated with improved integrative capacity 
of progenitor cells to organize into endothelial networks, as well as increased CXCR4 
expression [36].  In this study ischemic exercise training increased EPC number and 
function, while non-ischemic exercise appeared to improve only EPC function. 
 
Hyperbaric Treatment 
EPC trafficking is generally thought to be regulated by hypoxic gradients and induced by 
VEGF-mediated increases in bone marrow nitric oxide. Interestingly, Goldstein and 
colleagues found that hyperoxia induced by hyperbaric oxygen (HBO2) exposure 
paradoxically results in a signaling cascade similar to that induced by tissue hypoxia. In a 
hindlimb ischemia animal model, the researchers showed that the wound closure rate for a 
wound in the non-ischemic limb did not significantly improve in response to HBO2 
treatment, but a wound in the ischemic limb showed a significantly improved healing rate in 
the presence of HBO2. The researchers proposed that HBO2 treatment increases EPC 
mobilization from the bone marrow, but does not increase homing of EPCs into injured non-
ischemic tissues [37]. Gallagher and colleagues proposed a mechanism of action; they 
showed that HBO2 treatments increase nitric oxide synthase (NOS), which elevates NO in the 
blood. NO nitrosylates MMP-9 which cleaves membrane-bound stem cell factor (SCF), 
prompting EPC proliferation and migration [38]. Several other studies have also 
demonstrated that HBO2 treatment mobilizes EPCs from the bone marrow and stimulates 




Exogenous Drug Therapy 
Many studies have investigated the effects of certain drug therapies for inducing recruitment, 
migration, proliferation, and incorporation of EPCs into target vascular epithelium. Many 
drugs have proven useful in this respect, both in vitro, in animal models, and in human 
clinical trials.   
 
Vascular Endothelial Growth Factor (VEGF) 
VEGF is a growth factor that is upregulated in hypoxic cells via hypoxia inducible factor-1 
(HIF-1), and stimulates release of nitric oxide from endothelial cells. VEGF increases 
vascular permeability and exhibits a dose-dependent mitogenic and chemotactic effect on 
endothelial cells to promote new vessel formation [40]. VEGF is correlated with rapid but 
transient EPC recruitment after traumatic vascular injury [4], but has been tested more 
extensively in the context of therapeutic angiogenesis. Initial hindlimb ischemia studies 
evaluating VEGF therapy showed an increase in neovascularization and improvement in the 
hemodynamic deficit of the animal model [40].  Takeshita and colleagues demonstrated a 
significant dose-dependent augmentation in ischemic limb perfusion accompanied by 
increased collateral formation after intramuscular administration of VEGF [41]. 
 
However, VEGF does not seem to be a magic bullet.  The Regional Angiogenesis with 
Vascular Endothelial Growth Factor (RAVE) trial was a randomized study of adenoviral 
VEGF (AdVEGF) gene transfer for the treatment of PAD. A total of 105 patients with 
unilateral exercise-limiting intermittent claudication were randomized to receive low-dose 
AdVEGF, high-dose AdVEGF, or placebo, administered as 20 intramuscular injections to the 
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index leg in a single session. The change in peak walking time, ankle-brachial index, 
claudication onset time, and quality-of-life measures were similar among all three groups at 
12 and 26 weeks. In addition, AdVEGF administration was associated with increased 
peripheral edema, consistent with its known effect of increasing vascular permeability. The 
researchers were forced to conclude that VEGF-based treatment had limited utility since it 
was not associated with improved exercise performance or quality of life [42]. 
 
Granulocyte Colony Stimulating Factor (G-CSF) 
G-CSF, a growth factor for neutrophils, interferes with the CXCR4/SDF-1 receptor-ligand 
interaction, mobilizing hematopoietic stem cells into the bloodstream. Degradation of SDF-1 
in the bone marrow releases EPCs by disrupting the CXCR4/SDF-1 receptor-ligand 
interaction which sequesters these cells in the bone marrow. Upregulation of SDF-1 in 
peripheral tissues attracts EPCs from the bone marrow to the periphery, particularly to sites 
of tissue hypoxia and HIF-1 expression. In this way the CXCR4/SDF-1 receptor-chemokine 
interaction is instrumental for mobilizing and incorporating EPCs to sites of vessel injury and 
ischemia.  
 
Takahashi and colleagues found that in rabbits with hindlimb ischemia, circulating EPCs 
were augmented after pretreatment with GM-CSF, with a corresponding improvement in 
hindlimb neovascularization [43]. However, in a pilot study on STimulation of 
ARTeriogenesis (the START Trial), GM-CSF or placebo was delivered subcutaneously to 
patients with intermediate to severe intermittent claudication as treatment for PAD. This 
randomized controlled trial found no difference in the treatment and placebo groups in terms 
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of the primary outcome, walking time, or the secondary outcome, ankle-brachial index [44]. 
 
Notably, the CXCR4/SDF-1 interaction has been shown to simultaneously recruit bone 
marrow-derived smooth muscle cell progenitors to regions of vessel injury where medial 
smooth muscle cells undergoing apoptosis express SDF-1. Smooth muscle cell precursors 
may assist in vascular repair; however, this response has also been shown to result in 
pathological healing and neointimal hyperplasia [45].  
 
HMG CoA Reductase Inhibitors 
Known primarily for their lipid-lowering activity, HMG-CoA reductase inhibitors (statins) 
increase neovascularization by increasing circulating EPC number and/or augmenting EPC 
function. Vasa and colleagues studied 15 patients with angiographically documented stable 
CAD to determine the effect of statin therapy on circulating EPC number. These patients 
were prospectively treated with 40 mg of atorvastatin per day for 4 weeks. Statin treatment 
was associated with an approximately 1.5-fold increase in the number of circulating EPCs 
after one week, followed by sustained increased levels to approximately 3-fold throughout 
the 4-week study period [46]. Walter and colleagues demonstrated that statins increased 
circulating rat EPCs by 2.5-fold at 4 weeks [47].  Dimmeler and colleagues used a mouse 
model to show that statins potently augment EPC differentiation from mononuclear cells and 
CD34-positive hematopoietic stem cells isolated from peripheral blood [48]. 
 
Interestingly, statins, VEGF, erythropoietin, estrogen, and exercise all exert effects on EPCs 
via the PI3K/Akt signal transduction pathway. This observation suggests an essential role for 
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Akt in regulating hematopoietic progenitor cell mobilization, which is likely mediated 
through the eNOS pathway [49]. 
 
EPCs and Peripheral Vascular Disease (PVD): 
Most studies evaluating the effectiveness of stem cell therapy have used unpurified bone 
marrow containing a combination of EPCs, hematopoietic stem cells, and other cells. 
Asahara and colleagues originally described the incorporation of autologous CD34-positive 
mononuclear cells into foci of neovascularization in the rabbit hindlimb ischemia model [8]. 
Kalka and colleagues confirmed these studies using human EPCs transplanted into a nude 
mouse model, and found that blood flow recovery and capillary density in the ischemic 
hindlimb were markedly improved, and the rate of limb loss was significantly reduced. The 
rate of limb necrosis and auto-amputation was reduced by 50% compared to controls [15,50]. 
 
Tateishi-Yuyama and colleagues investigated the efficacy of autologous implantation of bone 
marrow-derived mononuclear cells (BMCs), including EPCs, into the ischemic limbs of 
patients with PAD. Twenty-two patients with bilateral leg ischemia were injected with BMCs 
in one leg and peripheral blood-derived mononuclear cells in the other. At four weeks, the 
ankle-brachial index was significantly improved in legs injected with BMCs compared with 
those injected with peripheral blood-derived mononuclear cells. Similar improvements were 
seen for transcutaneous oxygen pressure, rest pain, and pain-free walking time. These 
improvements were sustained at 24 weeks. The authors concluded that autologous 
implantation of BMCs could be safe and effective for achievement of therapeutic 
angiogenesis because of the natural ability of marrow cells to supply EPCs and to secrete 
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various angiogenic factors or cytokines [51].  Esato and colleagues demonstrated similar 
results in patients with PAD who had failed traditional medical treatment and/or surgical 
bypass procedures. After BMC transplantation, patients reported improved subjective 
symptoms [52]. 
 
Bartsch and colleagues reported early results of the TAM-PAD study (Transplantation of 
Autologous Mononuclear bone marrow stem cells in patients with Peripheral Arterial 
Disease). This study was designed to evaluate the use of combined intraarterial and 
intramuscular bone marrow-derived mononuclear cell (BMC) therapy for patients with 
moderate to severe intermittent claudication. They reported that two months after harvesting 
and delivering BMCs to the ischemic limb, pain-free walking distance increased 3.7-fold and 
the ABI was significantly improved after exercise and at rest [53]. Notably, after 13 months 
these positive effects persisted at their improved level [54]. 
 
Two additional studies evaluating BMCs in patients with PVD are worth mentioning. 
Higashi and colleagues evaluated BMC transplantation and its effect on endothelial 
dysfunction. They found that BMC implantation significantly improved the transcutaneous 
oxygen pressure, pain-free walking time, and endothelium-dependent vasodilation in patients 
with limb ischemia [55]. Lastly, Saigawa and colleagues noted that the clinical effectiveness 
of autologous bone marrow implantation, as measured by an improvement in ankle-brachial 
index, was strongly correlated with the number of CD34-positive cells delivered to the 




In contrast to the studies evaluating BMC therapy, Ishida and colleagues used only peripheral 
blood-derived mononuclear cells in treating patients with PAD. These cells were mobilized 
with G-CSF and then harvested and injected intramuscularly. After four weeks the 
researchers observed a significant improvement in ankle-brachial index, healing of ischemic 
ulcers, and increased mean maximum walking distance [57]. 
 
As a group, these studies suggest that the specific cell type, or the combination of cells and 
cytokines, required to generate beneficial healing effects in patients with PAD are still 
incompletely understood. 
 
Mononuclear Cells and Graft Patency: 
Although studies have not been performed with isolated EPCs, several studies have shown 
that some bone marrow-derived stem cells can colonize and epithelialize synthetic and 
biological vascular grafts and devices to render the foreign surface less thrombogenic. Shi 
and colleagues used a canine bone marrow transplantation model in which the marrow cells 
from the donor and recipient are genetically distinct. Between 6 and 8 months after 
transplantation, a Dacron graft, made impervious to prevent capillary ingrowth from the 
surrounding perigraft tissue, was implanted in the descending thoracic aorta. After 12 weeks 
the graft was retrieved, and cells with endothelial morphology were identified by silver 
nitrate staining. Using repeat polymorphisms to distinguish between the donor and recipient 
DNA, Shi and colleagues observed that only donor alleles were detected in DNA from 
positively stained cells on the impervious Dacron graft. These results strongly suggest that a 
subset of CD34-positive cells localized in the bone marrow can be mobilized to the 
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peripheral circulation and can colonize endothelial flow surfaces of vascular prostheses [20]. 
 
In a similar study, Bhattacharya and colleagues demonstrated accelerated endothelialization 
on polyethylene terephthalate (PET) grafts treated with enriched CD34-positive autologous 
bone marrow cells in a canine model. The authors used composite grafts implanted in the 
descending thoracic aorta for 4 weeks. The composite grafts had a 4-cm PET graft in the 
center flanked by two 4-cm standard PTFE grafts; the entire composite was coated with 
silicone rubber to make it impervious, and the PET segment was shielded from perigraft and 
pannus ingrowth. On the day before surgery, 120 mL of bone marrow was aspirated, and the 
CD34-positive cells were enriched. During surgery, these cells were mixed with venous 
blood and seeded onto the PET segment of composite study grafts; the control grafts were 
treated with venous blood only. After harvesting, there was a significant increase in surface 
endothelialization on the seeded grafts (approximately 92% vs. 27%) with markedly 
increased microvessels in the neointima, graft wall, and external area compared with control 
grafts [58]. 
 
In humans, Peichev and colleagues found that the neointima formed on the surface of left 
ventricular assist devices was colonized with cells expressing the markers CD34, CD133, and 
VEGF-R2, consistent with the EPC phenotype [22].  Furthermore, Matsuo and colleagues 
showed that senescent EPCs may be a risk factor for in-stent restenosis in a study of 46 
patients who underwent coronary stenting. Blood samples were collected at the time of 
follow-up coronary angiography after stent placement. Patients (n=16) with in-stent 
restenosis, defined as greater than 40% stenosis, had decreased EPC numbers and increased 
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senescent cells compared to patients without restenosis (n=30). There was no significant 
difference in angiogenic growth factors secreted by EPCs between the two groups. On 
multivariate analysis, an increased number of senescent EPCs was the independent factor 
associated with in-stent restenosis (odds ratio 1.10) [59]. 
 
Shin’oka and colleagues have pioneered the exciting field of tissue-engineered biodegradable 
grafts seeded with autologous bone marrow cells for the repair of cardiovascular defects in 
children. Previous studies showed that bone marrow cells contribute to the construction of 
tissue-engineered vascular autografts (TEVA) in vivo, and since these constructs contain 
living cells, they may have the ability to grow, self-repair, and self-remodel. These 
characteristics are especially desirable in growing children to decrease the number of 
necessary revision surgeries. Biodegradable conduits (n=23) and patches (n=19) were 
implanted in children for extracardiac total cavopulmonary connection and congenital heart 
defects, respectively. TEVA were only implanted in low pressure (venous or pulmonary 
artery) systems. Patients received anticoagulation therapy for 3 to 6 months post-operatively. 
Intermediate-term follow-up after a median of 16.7 months showed no complications such as 
thrombosis, stenosis, or obstruction of TEVA. There was no evidence of aneurysm formation 
or calcification. All tube grafts were patent, and the diameter of the tube grafts increased to 
approximately 110% of the implanted size over time. These results show that after 
intermediate-term follow-up, TEVA are safe and feasible in pediatric cardiovascular surgery 
and have excellent hemodynamic performance, even after cessation of anticoagulation 





EPC therapy refers to an intervention that targets the recruitment, mobilization, proliferation, 
and incorporation of EPCs into injured vessels and ischemic tissues with the purpose of 
augmenting healing and tissue regeneration in animal models and in patients with severe 
vascular disease. 
 
In addition to autologous transplantation of EPCs as described previously, certain factors 
may be important in augmenting EPC function and increasing ischemic limb perfusion. 
Murohara and colleagues showed a significant role for nitric oxide and endothelial nitric 
oxide synthase (eNOS) in revascularization of ischemic limbs using L-arginine dietary 
supplementation [49].  Notably Takahashi and colleagues found that the development of 
regional ischemia in animal models increased the frequency of circulating EPCs, and that 
pretreatment with GM-CSF further increased EPC numbers with a corresponding 
improvement in hindlimb neovascularization. These findings indicate that circulating EPCs 
may be mobilized endogenously in response to tissue ischemia or exogenously by cytokine 
therapy to assist in neovascularization of ischemic tissues [43]. 
 
As these therapies become established, three categories of patients may be considered for 
therapy with EPCs. The first category includes patients with severe ischemic peripheral 
vascular disease, a threatened limb, and no surgical or endovascular options for 
reconstruction. The second category includes patients with severe comorbid disease who are 
not operative candidates for potential procedures. The third category includes patients with 
bypass grafts or stents in place; under these circumstances EPC therapy may improve conduit 
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survival by preventing restenosis [15].  However, EPC therapy has the potential to stimulate 
neovascularization in tumors, and therefore is not indicated for patients with cancer or at high 
risk for acquiring cancer [63,64]. 
 
Another important consideration in EPC therapy is the possibility of resultant neointimal 
hyperplasia after arterial injury due to the contribution of smooth muscle cells stimulated by 
SDF-1. Zernecke and colleagues describe the involvement of local SDF-1alpha and its 
receptor CXCR4 in neointimal hyperplasia via recruitment of bone marrow-derived smooth 
muscle cell progenitors. After arterial injury, SDF-1alpha is expressed in medial smooth 
muscle cells. SDF-1alpha binds to platelets at the site of injury, triggers CXCR4- and P-
selectin-dependent arrest of progenitor cells on injured arteries or matrix-adherent platelets, 
and preferentially mobilizes and recruits progenitors for neointimal smooth muscle cells [45]. 
 
In patients that are selected as candidates for EPC therapy, several methods for augmentation 
of EPC number and function exist. Strategies include improving the intrinsic function of a 
patient’s native cells, processing of precursor cells, providing allogeneic progenitors, or using 
a combination of these approaches. 
 
Most studies evaluating EPC therapy for patients with vascular disease used either unpurified 
bone marrow samples or a combination of EPCs, hematopoietic stem cells, and other cells 
derived from bone marrow. Thus it is unclear whether EPCs alone are sufficient to repair 
vascular injury, or whether other supporting cells or components of the bone marrow are also 
necessary for a therapeutic effect. This is a critical point, as introduction of nonessential cells 
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may be associated with aggravation of inflammation and vascular injury, thereby 
exacerbating the problem for which the patient seeks treatment [13]. 
 
Chapter II:  Monocytes and Peripheral Vascular Disease (PVD) 
 
Overview of PVD: 
Vascular disease has a very high prevalence and mortality rate in the United States.  
According to the Centers for Disease Control and Prevention (CDC), cardiovascular and 
cerebrovascular disease are the first and third leading causes of death in the United States, 
accounting for approximately 40% of all deaths in 2004. The American Heart Association 
analysis of 2004 Heart Disease and Stroke Statistics categorizes coronary artery disease 
(CAD), stroke, hypertension, heart failure, and peripheral vascular disease (PVD) as subsets 
of Cardiovascular Disease. They estimate that in the United States the total cost of these 
diseases, which includes funds spent on healthcare as well as indirect costs associated with 
loss of work, will be $432 billion in 2007 [65,66]. 
 
These vascular conditions are interrelated due to the fact that vascular disease is often 
systemic. Events such as myocardial infarction, stroke, and acute ischemia of the lower 
extremities may be a manifestation of the same disease process in different organs or 
vascular beds. Since atherosclerosis and other risk factors for PVD also predispose to CAD 
and stroke, these patients often have coexistent cardiovascular and cerebrovascular disease. 
The Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial 
showed that 41.1% of patients with PVD had concurrent CAD or cerebrovascular disease, 
32 
 
and 8.6% had disease in all three vascular beds [67]. Patients with symptomatic PVD have a 
5-year mortality of almost 30% due to cardiovascular and cerebrovascular events, and those 
with large-vessel PVD have a relative risk of 5.9 (95% CI) for death from cardiovascular 
disease within ten years [68-71]. 
 
Peripheral arterial disease (PAD) is a subset of PVD. In the lower extremities, PAD involves 
obstruction of blood flow in the major arteries that supply the lower limbs. Atherosclerotic 
disease is the most common culprit, leading to stenosis and partial or total occlusion of these 
large arteries, resulting in various degrees of ischemia. PAD causes significant morbidity by 
adversely affecting mobility, function, and the ability to perform activities of daily living.  
 
The clinical severity of PAD is commonly classified using two different modalities, namely 
the ankle-brachial index (ABI) and the Fontaine Stages. The ABI is calculated by dividing 
the systolic blood pressure at the ankle by the higher of the two systolic brachial blood 
pressures. A normal ABI is approximately 1.0-1.1, and increasing severity of PAD is 
associated with decreasing ABI. Fontaine Stages are defined as follows: Stage I is 
asymptomatic (ABI approximately 0.8-0.9), Stage IIa corresponds to the presence of mild 
claudication and Stage IIb represents moderate to severe claudication (ABI approximately 
0.5-0.8, depending on severity of claudication), Stage III corresponds to the presence of 
ischemic rest pain (ABI approximately 0.3-0.5), and Stage IV to the presence of tissue loss 
(ulceration or gangrene, ABI approximately 0.3-0.5) [72,73]. Notably, patients may have 




The initial signs of lower extremity PAD (Fontaine Stage I) include trophic changes, where a 
chronically diminished blood supply results in thickened skin and toenails, as well as loss of 
hair growth on the toes and feet. Patients are usually asymptomatic at this point. Intermittent 
claudication is the next stage in severity (Fontaine Stage II), and is the earliest and most 
frequent presenting symptom [73]. Patients typically complain of pain in the calf or thigh 
muscles upon ambulation, due to the increased demand for oxygen by the working muscles 
and the inability of the vessels to increase the supply of blood to the ischemic tissue. 
Importantly, intermittent claudication is reproducibly produced by exercise and relieved 
within 10 minutes after exercise is discontinued. As the disease progresses in severity 
patients may develop rest pain (Fontaine Stage III), which is typically described as a sharp 
pain in the foot at rest, most commonly when lying flat in bed at night. This pain is 
commonly relieved by dependency, and patients may dangle their feet off the bed for relief. 
In the late stages of PAD, tissue hypoperfusion may lead to tissue loss (Fontaine Stage IV), 
where the blood supply is insufficient to sustain the basic metabolic requirements of the 
distal tissues such that ulceration and gangrene result.  Major amputation is eventually 
required in more than a third of patients with tissue loss [73]. Patients with rest pain and/or 
tissue loss are identified as having critical limb ischemia (CLI) which is an important 
predictor of poor prognosis, with a 2-year mortality rate of 31.6% according to  a study by 
the I.C.A.I. Group (Gruppo di Studio dell'Ischemia Cronica Critica degli Arti Inferiori) [74]. 
 
Screening for PAD in the absence of symptoms utilizes the ABI measurement. A resting ABI 
of ≤ 0.90 is caused by hemodynamically significant lower extremity arterial stenosis and is 
commonly used as a threshold below which a patient is given the diagnosis of PAD. In 
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symptomatic individuals, a resting ABI of ≤ 0.90 is approximately 95% sensitive for 
detecting angiographically significant PAD and almost 100% specific in identifying healthy 
individuals [72]. Interestingly the Edinburgh Artery Study, using duplex scanning, found that 
one-third of patients with asymptomatic PAD had complete occlusion of a major artery to the 
leg [75]. The Rotterdam Study documented the frequency of intermittent claudication and 
PAD in a large study group of 7715 patients. They found that although the frequency of 
intermittent claudication was between 1% and 4.6% depending on the age group, the actual 
prevalence of PAD (as defined by an ABI of ≤ 0.9) was 16.9% in men and 20.5% in women 
over age 55 [76]. The Inter-Society Consensus for the Management of Peripheral Arterial 
Disease (TASC II) agreed with this assessment, stating that “For every patient with 
symptomatic PAD there are another three to four subjects with PAD who do not meet the 
clinical criteria for intermittent claudication” [72].  
 
In addition, the TASC II Consensus notes that although intermittent claudication is an 
important finding in many patients with PAD, the presence or absence of this symptom does 
not always predict the presence or absence of PAD. This is due to the fact that other disease 
processes, such as spinal stenosis, can produce symptoms that mimic intermittent 
claudication in a patient without PAD. Additionally, patients with sedentary lifestyles, severe 
deconditioning, heart disease or other comorbidities which limit exercise may not report 





Since the majority of patients with significant PAD are asymptomatic, and since it is 
uncommon to screen an asymptomatic patient, the exact prevalence of PAD is difficult to 
estimate [73]. However, studies have suggested that, when defined as an ABI of ≤ 0.9, PAD 
has a prevalence of approximately 3% in patients under 60 yrs old to approximately 20% in 
patients over 75 yrs old [69,75,77].  
 
PAD is usually diagnosed by history and physical exam alone. A high index of suspicion in 
patients with multiple risk factors is recommended, even if the patient does not complain of 
lower extremity symptoms. The diagnosis of asymptomatic PAD has little clinical relevance 
with respect to the lower extremities, but as a strong marker for future cardiovascular events, 
early diagnosis and intervention are an important aspect of preventative treatment [71]. As 
alluded to previously, CAD is the most common cause of death in PAD patients, accounting 
for 40% to 60% of deaths, with cerebral artery disease accounting for 10% to 20% of deaths, 
and only 20% to 30% of patients dying of non-cardiovascular causes [72].  
 
There are many risk factors for PAD, only the most significant of which are presented here. 
All of the following data and statistics are derived from the TASC II Consensus. As 
suggested previously, the prevalence of symptomatic PAD increases with age, following a 
smooth curve from approximately 0.5% in patients 30-34 years old to approximately 6.5% in 
patients 70-74 years old. There also seems to be a correlation between PAD and race: an ABI 
≤ 0.9 was more common in non-Hispanic blacks (7.8%) than whites (4.4%). The prevalence 
is also slightly greater in men than women, and this difference increases with the severity of 
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disease: in patients with intermittent claudication the ratio of men to women is between 1:1 
and 2:1, but in patients with CLI the ratio increases to 3:1 [72]. 
 
Smoking is one of the most significant and longest-known risk factors for PAD, recognized 
since 1911 when it was documented that symptoms of intermittent claudication were three 
times more common in smokers compared to nonsmokers. Furthermore, smoking has a dose-
dependent effect on PAD; there is a direct correlation between the number of cigarettes 
smoked and the severity of disease. Heavy smokers have a four-fold risk of developing 
intermittent claudication compared to nonsmokers, and smoking cessation is associated with 
a decline in the incidence of PAD symptoms [72]. The Edinburgh Artery Study found that 
the relative risk of intermittent claudication was 3.7 in smokers compared to 3.0 in ex-
smokers who had abstained for five years [75]. 
 
Overall, PAD is twice as common in patients with diabetes that in patients without. The 
correlation is impressive: in patients with diabetes, for every 1% increase in hemoglobin 
A1c, there is a 26% increase in risk of PAD. The presence of peripheral neuropathy and 
decreased resistance to infection in diabetic patients complicates the picture, and the 
subsequent need for a major amputation is five to ten times more common in patients with 
diabetes than in patients without. Notably, insulin resistance is a risk factor even in patients 
without diabetes [72]. 
 
Hypertension is associated with all types of vascular disease but does not predict the risk of 
developing PAD as highly as smoking or diabetes. Hyperlipidemia, on the other hand, has a 
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stronger correlation with PAD. The Framingham Study showed that a fasting cholesterol 
level of greater than 270 mg/dL was associated with a doubling of the incidence of 
intermittent claudication, but it was the ratio of total to high density lipoprotein (HDL) 
cholesterol that was the best predictor of occurrence of PAD. Other factors such as markers 
of inflammation, hyperviscosity, hypercoagulable states, and hyperhomocysteinemia may 
also be risk factors for a poor prognosis [72]. 
 
Treatment options for PAD are aimed at two targets: decreasing the risk factors for 
atherosclerosis and improving the lower extremity symptoms of PAD. In all cases except for 
acute ischemic events, it is advisable to begin treatment with efforts to decrease the risk 
factors associated with atherosclerotic disease, with the intent of reducing the risk of life-
threatening thrombotic events such as myocardial infarction and stroke, as well as improving 
the symptoms of limb ischemia.  Decreasing risk factors involves lifestyle modification and 
pharmacotherapy. A cornerstone of the management for PAD involves smoking cessation. 
Other important lifestyle modifications include increased exercise and improved diet. In 
addition, a combination of lifestyle modification and pharmacotherapy to control diabetes, 
hyperlipidemia, and hypertension is recommended. Administration of an antiplatelet agent 
such as aspirin or clopidogrel is now a common practice [72].  
 
For patients with intermittent claudication, exercise rehabilitation has been shown to provide 
significant clinical benefit, improving exercise performance and community-based walking 
ability. It is interesting to note that the benefits correlate more strongly with supervised vs. 
unsupervised programs, with treadmill exercise vs. weight training, with experience of severe 
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claudication pain during exercise, and with 6 months or more of training [72]. In addition, 
agents such as cilostazol (a phosphodiesterase III inhibitor with vasodilator, metabolic, and 
antiplatelet activity) as well as naftidrofuryl (a 5-hydroxytryptamine antagonist which may 
improve muscle metabolism) have been shown to improve peak treadmill performance and 
quality of life in some studies [72].   
 
As mentioned previously, the trials evaluating the use of VEGF and GM-CSF in patients 
with intermittent claudication showed no beneficial effects, so these agents are not 
recommended for treatment. To summarize, the RAVE trial randomized patients with 
intermittent claudication to receive adenoviral VEGF (AdVEGF) gene transfer or placebo for 
the treatment of PAD. The researchers concluded that VEGF-based treatment had limited 
utility since it was not associated with improved exercise performance or quality of life [42]. 
In the START Trial, GM-CSF or placebo was delivered subcutaneously to patients with 
intermediate to severe intermittent claudication as treatment for PAD. This randomized 
controlled trial found no difference in the treatment and placebo groups in terms of the 
primary outcome, walking time, or the secondary outcome, ABI [44]. 
 
In severe cases refractory to conservative treatment, where intermittent claudication 
interferes significantly with a patient’s lifestyle or work and adversely impacts quality of life, 
revascularization surgery may be considered for symptoms of claudication alone.   
 
For patients with critical limb ischemia (CLI), the primary goals of treatment include the 
following: relief of ischemic rest pain, healing of ulceration, prevention of limb loss, and 
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improvement of patient quality of life, function, and survival. Most patients with CLI will 
ultimately require a revascularization procedure. However, some patients with severe 
comorbidities or poor predicted post-revascularization outcome in terms of quality of life or 
function may be treated with a primary amputation. For patients with CLI who are awaiting a 
revascularization procedure, who decline amputation, or who have no surgical options for 
reconstruction, pain control with regularly-dosed narcotics is often required. Pressure relief 
and antibiotics may assist in ulcer healing. In addition, intermittent IV infusion of 
prostanoids (prostaglandin-E1 or iloprost) may help reduce rest pain and heal ischemic 
ulcers, though these agents are more commonly used in Japan than in the United States. 
Notably, recent trials do not support the benefit of prostanoids in promoting amputation-free 
survival [72]. Hyperbaric oxygen therapy may be beneficial in reducing the risk of major 
amputation in patients with diabetic foot ulceration according to a Cochrane review, but 
methodological issues and the studied populations limit its generalizability to all patients 
with CLI [72]. 
 
For patients with CLI who are surgical candidates, several options exist. For localized 
disease, techniques include percutaneous angioplasty and stenting or open surgical 
endarterectomy. The exact distribution and severity of the lesions, as well as individual 
patient factors, dictate the recommended intervention. For more extensive disease, open 
peripheral bypass procedures are recommended, provided there is an appropriate target vessel 
for reconstruction [72]. It is important to note that for patients undergoing angioplasty or 
surgery it is necessary to obtain an angiogram to localize and characterize the lesions, and to 
identify inflow and outflow vessels as necessary. Angiography requires that a patient have 
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acceptable renal function or the option for hemodialysis. 
 
Percutaneous angioplasty and stenting has the distinct advantage that it is minimally invasive 
and thus less stressful than an open surgical procedure, making it attractive for patients with 
comorbidities and high risk for complications. However, the long-term patency rates are 
inferior to that of open surgical procedures. For infrainguinal stenting, the 3-year patency 
rates are below 60%; depending on the study quoted, they range from 42% to 72% [73]. As 
expected, however, the TASC II Consensus reports that perioperative complication and 
mortality rate are superior to those of open surgical procedures [72]. Importantly, 
percutaneous angioplasty and stenting interventions have dismal results when used distal to 
the knee, so for patients with infrapopliteal disease and CLI, autogenous vein bypass is the 
first line of reconstructive therapy [73].  
 
In general, endarterectomy is performed for local disease in patients who are appropriate 
candidates, and infrainguinal bypass procedures are performed for more extensive disease. 
Notably, patients with CLI tend to have more extensive disease and often require open 
bypass reconstruction, provided there is an adequate target vessel. Typically autogenous vein 
grafts are used for bypass procedures if they are available and of sufficient caliber. When 
using a non-diseased saphenous vein graft of adequate caliber, the patency rate is approx 70-
80% at 5 years irrespective of whether the vessel is reversed or incorporated in situ. In 
patients without an available autologous vein for use as a graft, a prosthetic graft may also be 
used. These grafts have better results when the outflow is to the above-knee (AK) popliteal 
artery, as patency rates drop sharply when the outflow is infrapopliteal. For this reason the 
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use of a native vessel is recommended if the distal anastomosis is below the knee. According 
to the TASC Consensus, autologous vein grafts spanning from the femoral to the below-knee 
(BK) popliteal artery have a patency rate of approximately 70% at 5 years. In contrast, 
prosthetic grafts spanning from the femoral to the BK popliteal artery have a patency rate of 
approximately 30% at 5 years [72].  
 
As mentioned previously, the goals of peripheral bypass surgery include resolution of 
ischemia, healing of ulcers and wounds, improvement in patient symptoms, function, and 
quality of life, and preservation of the extremity. However, bypass grafts are not without 
their problems. In patients with preoperative limited healing potential, the risk of 
postoperative delayed wound healing and infection are very real. In addition, grafts may 
thrombose acutely or after several months or years. Patients must remain on anticoagulation 
and must have a high index of suspicion for complication so that if problems arise they can 
be treated emergently.  
 
Graft patency is intimately correlated with graft incorporation and the natural healing 
process. These processes are different depending on the type of graft; specifically, whether a 
native vein or a prosthetic graft is used. During vein graft incorporation there is smooth 
muscle infiltration and extracellular matrix deposition as the vein graft adapts to the arterial 
environment. In some cases exuberant healing may be pathologic, resulting in neointimal 
hyperplasia, vein graft stenosis, and subsequent graft failure. In prosthetic grafts, 
incorporation involves the deposition of a layer of endothelial cells on the flow surface of the 
grafts, which assists in making the graft less thrombogenic. However, if there is a disruption 
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or failure of this process, the graft may become thrombogenic, predisposing to occlusion and 
failure [78-80]. 
 
Cell-Based Therapy for PVD: 
As previously described, mononuclear cells (MNCs) and endothelial progenitor cells (EPCs) 
are two populations of cells found in the bone marrow and periphery which are associated 
with vascular protection and healing. The circulating MNC fraction consists of 
approximately 85% lymphocytes, 15% monocytes, and 0.03% EPCs [13]. EPCs are thought 
to assist with reendothelialization and neovascularization in response to acute or chronic 
vascular injury; in addition, EPC numbers directly correlate with vascular protection and 
healing, and inversely correlate with the severity of vascular disease.  
 
Prior studies have used bone marrow-derived MNCs to increase neovascularization and ulcer 
healing by direct injection into the limbs of patients with unreconstructable limb ischemia. In 
addition, circulating peripheral MNCs have been investigated with similar beneficial effects. 
The protective and healing properties of the MNC fraction have been attributed to EPC 
activity; however it is possible that the monocyte component plays an active role in vascular 
healing and that monocytes are a clinically-relevant surrogate marker for EPCs. 
 
In summary, Tateishi-Yuyama and colleagues investigated the efficacy of autologous 
implantation of bone marrow-derived mononuclear cells (BMCs), including EPCs, into the 
ischemic limbs of patients with PAD. At four weeks, they noted significant improvement in 
ABI, transcutaneous oxygen pressure, rest pain, and pain-free walking time [51]. Bartsch and 
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colleagues reported early results of combined intraarterial and intramuscular BMC therapy 
for patients with moderate to severe intermittent claudication. Two months after harvesting 
and delivering BMCs to the ischemic limb, pain-free walking distance increased 3.7-fold and 
the ABI was significantly improved after exercise and at rest [53]. Notably, after 13 months 
these positive effects persisted at their improved level [54]. In addition, Saigawa and 
colleagues noted that the clinical effectiveness of autologous bone marrow implantation, as 
measured by an improvement in ABI, was strongly correlated with the number of CD34-
positive cells delivered to the ischemic limb [56]. In contrast to the studies evaluating BMC 
therapy, Ishida and colleagues used only peripheral blood mononuclear cells in patients with 
PAD. These cells were mobilized with G-CSF and then harvested and injected 
intramuscularly. After four weeks the researchers observed a significant improvement in 
ABI, healing of ischemic ulcers, and increased mean maximum walking distance [57].  
 
These studies suggest that the specific cell type, or the combination of cells and cytokines, 
required to generate beneficial healing effects in patients with PAD are still incompletely 
understood. However, the implications of these studies for patients with unreconstructable 
lower extremity critical limb ischemia are very exciting. The patients most likely to benefit 
from cell-based therapy include those patients with CLI and no surgical or endovascular 
options for reconstruction, as well as patients with severe comorbid disease who are not 




Monocytes and Peripheral Arterial Disease (PAD): 
The relationship between monocytes and advanced atherosclerosis is well established, since 
monocytes are known to contribute to the foam cells of the lesions.  The following key 
processes outline the importance of monocytes in the development of atherosclerosis [81]:  
1) endothelial injury;  2) intimal cholesterol accumulation and monocyte invasion with 
subsequent foam cell formation;  3) migration and proliferation of smooth muscle cells with 
expression of extracellular matrix;  4) local thrombus formation with secondary organization;  
5) calcification and /or plaque rupture;  and 6) final occlusion due to plaque rupture or 
thrombus formation [81]. 
 
The fact that EPCs are a component of the circulating monocyte fraction adds relevance to 
the study of monocytic populations in the setting of vascular disease. However, only a few 
studies have specifically addressed circulating monocytes in patients with PAD. Several 
studies have shown that patients with PAD have increased inflammatory markers, including 
monocyte chemoattractant protein-1 (MCP-1), a paracrine factor which mediates the 
recruitment of monocytes. Nylaende and colleagues studied the relationship between 
biochemical markers of inflammation and the diagnostic measures of PAD, including ABI, 
maximum treadmill walking distance, and angiographic score. In 127 patients with 
angiographically verified PAD, MCP-1 and CD40L were independently and significantly 
correlated with the angiographic score [82]. A study by Petrkova and colleagues also found 
that MCP-1 is elevated in patients with PAD compared to controls [83].  
 
Hoogeveen and colleagues, as part of the Atherosclerosis Risk in Communities study,  
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demonstrated that there was a significant association of MCP-1 with PAD, independent of 
traditional coronary heart disease risk factors, with an odds ratio of 2.14 (95% CI) for the 
highest MCP-1 tertile compared to the lowest. Incident coronary heart disease risk increased 
significantly for each standard deviation difference in MCP-1 level, independently of other 
cardiovascular risk factors, including inflammatory markers. These data show that MCP-1 is 
associated with atherosclerotic disease. [81]. 
 
The correlation between PAD and inflammation is known, but what makes these studies 
interesting is that MCP-1 has also been associated with angiogenesis. A study by Muhs and 
colleagues in 2004 followed up prior observations that local infusion of recombinant MCP-1 
could enhance collateral artery formation in rabbit and pig hindlimb models. Owing to the 
clinical disadvantages of protein infusion, Muhs and colleagues developed a nonviral, 
liposome-based MCP-1 gene transfer in a pig hindlimb ischemia model. Development of 
conductance as a measure of functionally relevant collateralization was evaluated in occluded 
as well as untreated limbs of each treatment animal and compared to control animals. The 
MCP-1 and control liposomes were locally delivered at the time of femoral artery occlusion. 
Two weeks after occlusion, collateralization was determined as changes in peripheral 
hemodynamic conductance, peripheral over aortic blood pressure ratio, and angiographically 
visible morphology of the peripheral vessel tree. Nonviral MCP-1 gene transfer significantly 
improved peripheral conductance (MCP-1 = 23.81 ± 2.81% and control = 11.69 ± 2.78%) as 
well as the ratio of peripheral over aortic blood pressure (MCP-1 = 0.75 ± 0.02% and control 




Another relevant study by Seidler and colleagues reported that intra-arterial infusion of 
MCP-1 in a pig model after unilateral femoral artery occlusion stimulated collateral artery 
growth. Specifically, infusion of two micrograms per minute of MCP-1 for six hours was 
sufficient to double the arterial conductance at two weeks and sustain a significant increase in 
arterial conductance after six weeks [85]. 
 
These studies suggest that ischemic areas are capable of angiogenesis and are responsive to 
monocytes, stimulating a monocyte influx by release of the chemoattractant MCP-1.  Since 
human patients with PAD and CAD have elevated plasma MCP-1, the connection between 
monocytes and relief of ischemia is plausible. However, the preceding studies did not 
correlate the levels of MCP-1 or the severity of PAD with numbers of circulating monocytes. 
This data would be helpful with respect to the determination of the effector cell.  
 
To our knowledge, there is only one study in the literature that evaluated patients with PAD 
and circulating monocyte number. In 2005 Nasir and colleagues reported the results of a 
study in 3949 patients followed as part of the National Health and Nutrition Examination 
Survey (NHANES).  The objective of the study was to assess the independent association of 
white blood cell (WBC) types and other inflammatory markers with the presence of reduced 
ABI, a marker of subclinical PAD. All subjects had no known vascular disease, and 
subclinical PAD was defined as an ABI < 0.9 in at least one leg. The authors found that 
elevated monocytes were the only specific WBC type that independently predicted the 
presence of atherosclerotic PAD. Even after adjustment for traditional cardiovascular risk 
factors, the odds ratio of PAD when comparing the highest to the lowest quartiles was 2.24 
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(95% CI). When WBC types and inflammatory markers were simultaneously included in the 
full model, the corresponding odds ratio was 1.91 (95% CI).  Neutrophil counts, C-reactive 
protein (CRP) levels, and fibrinogen levels did not have significant odds ratios. Nasir and 
colleagues thus showed that elevated monocytes were significantly and independently 
associated with PAD in a representative sample of the U.S. population after adjustment for 
other inflammatory markers [86]. Notably, all of these patients had subclinical PAD, 
suggesting that even patients with minimal atherosclerosis and no clinical ischemia may 
activate the monocyte fraction of the WBC population. 
 
Together these studies suggest that elevated MCP-1 and increased monocyte numbers 
correlate with tissue ischemia in patients with PAD. It is plausible that ischemic tissues 
release MCP-1 into the bloodstream to recruit monocytes into ischemic areas and promote 
vascular healing. Since monocytes and EPCs are components of the mononuclear cell 
fraction which has been shown to be responsible for vascular healing in many prior studies, 
this healing process may involve EPCs, monocytes, or both.  Although this theory explains 
many observations, it may further blur the distinction between EPCs and monocytes. On the 
other hand, it may also provide a novel and clinically-relevant surrogate marker for 
circulating EPCs. 
 
Distinguishing EPCs and Monocytes: 
As suggested earlier, the lineage of EPCs is not entirely known. In addition, many types of 
cells may be precursors to endothelial cells. Monocytes are closely related to EPCs; they are 
thought to be derived from common precursors and to give rise to similar daughter cells. This 
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is shown in Figure 1, where it is clear that the lineage of EPCs and monocytes intersect; 
however, Figure 1 is an oversimplified representation of EPC and monocyte lineage.  
 
In fact, a very recent study by Sieveking and colleagues isolated and defined different 
populations of putative EPCs; they have called them early endothelial progenitor cells (early 
EPCs) and late outgrowth endothelial cells (late OECs). Early EPCs, which appear in culture 
after 4 to 7 days, are similar to those originally described by Asahara and colleagues [8] and 
have been used in therapeutic studies [50]. In contrast, late OECs appear in culture after 14 to 
21 days, and form colonies with high proliferation rates. These two different populations 
have been classified as EPCs because they both express endothelial markers [87]. 
 
Sieveking and colleagues identified these subpopulations by using a novel endothelial cell-
specific angiogenesis assay that highlights strikingly different angiogenic properties of 
different putative EPCs and permits detailed functional characterization of EPCs. The 
researchers found that late OECs, but not early EPCs, form vascular networks in vivo and 
incorporate into vascular networks. In contrast, early EPCs, but not late OECs, augment 
angiogenesis in a paracrine fashion [87]. 
 
According to Sieveking and colleagues, since the differentiated fate of any putative 
endothelial progenitor cell is necessarily an endothelial cell, de novo tubulogenesis and 
incorporation into established vascular networks are important functional criteria by which 
putative EPCs should be assessed. Thus the researchers suggest that early EPCs are not true 
progenitors of endothelial cells but a monocytic cell capable of indirectly facilitating 
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angiogenesis in a paracrine fashion [87]. Figure 2 shows a proposed lineage diagram for 
EPCs that incorporates these new findings. 
 
The results generated by Sieveking and colleagues confirm an important study by Yoder and 
colleagues, which reported that early EPCs are cells of low proliferative potential that are 
hematopoietic in origin and differentiate into macrophages rather than endothelial cells in 
culture [26]. In addition, a study by Yoon and colleagues suggested that the paracrine factors 
secreted by the monocytic early EPCs include VEGF and IL-8, and that both early EPCs and 
late OECs have receptors for these cytokines [88]. Notably, there was no mention of MCP-1 
in any of these studies.  
 
Although the connections are as yet undefined, there is a wide array of literature that suggests 
that the interplay between the following three related concepts may be significant: the known 
capability of the mononuclear cell fraction, composed of lymphocytes, monocytes, and 
EPCs, to participate in vascular healing with clinically relevant effects; the synergistic 
relationship between EPCs and monocytes in terms of paracrine stimulation, which 
orchestrates incorporation of EPCs and formation of vascular networks; and the evidence that 
patients with PAD have higher levels of paracrine factors (MCP-1) and greater numbers of 
circulating monocytes than controls. These findings support a unifying theory where 
monocyte activity contributes to relief of ischemia in patients with PAD. While the exact 
mechanism is unclear, it is plausible that increased circulating monocytes, recruited from the 
bone marrow to ischemic areas via MCP-1, stimulate EPCs that subsequently contribute to 
vascular healing.  
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Statement of Purpose/Hypothesis/Specific Aims: 
 
Monocytes may contribute to the healing process in patients with peripheral vascular disease. 
Since ischemia appears to increase numbers of circulating monocytes, which in turn may 
stimulate EPC activity, we hypothesize that ischemic areas secrete paracrine factors such as 
MCP-1 to recruit bone marrow-derived monocytes into the circulation. These monocytes 
may then recruit EPCs that participate in angiogenesis and resolution of ischemia.  In patients 
with critical limb ischemia requiring peripheral arterial bypass surgery, the relief of ischemia 
by endogenous mechanisms is insufficient despite elevated levels of monocytes and 
paracrine factors, possibly due to an impaired EPC response. We hypothesize that successful 
surgical revascularization resolves ischemia and diminishes the stimulus for monocyte 






The records of all consecutive lower extremity peripheral bypass surgery cases performed at 
the VA Connecticut Healthcare Systems (West Haven, CT) between July 2002 and June 
2007 were reviewed.  
 
Patients were included in the study if they had a preoperative complete blood count (CBC) 
with differential recorded within one year prior to bypass surgery as well as a postoperative 
CBC with differential recorded between four months and 1.5 years after performance of the 
bypass surgery. The primary study time frame is defined as the time bounded by the dates of 
these lab tests.  
 
Patients were excluded from the study if the surgery was a revision, in cases where staged 
surgeries for bilateral lower extremities resulted in overlapping lab tests, and if the bypass 
surgery was an inflow procedure (with target vessel proximal to the AK popliteal artery). In 
addition, procedures complicated by limb-threatening graft failure within the study time 
frame were excluded; for example, if graft thrombosis required graft revision or amputation, 
or if persistent graft infection required graft removal or lifetime suppressive antibiotics. 
 
Patient risk factors were determined by thorough chart review. Demographic variables 
included the following: age, sex, diabetes, statin therapy, smoking status (never, prior, or 
current smoker), and affected extremity (left or right).  Operative data included the type of 
graft (native or prosthetic) and the outflow vessel (AK popliteal, BK popliteal or tibial).  
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Outcome variables included the following: graft status (patent or thrombosed), limb status 
(intact or amputation), and mortality.  Patient information with respect to the outcome 
variables was gathered until the date of last patient contact, which extended beyond the 
primary study time frame.  
 
The primary dependent variable of interest in this study was the monocyte count ratio, which 
was used to determine whether there was a change in monocyte count with any given risk 
factor.  Each cell count was derived from the CBC by multiplying the absolute white blood 
cell (WBC) count by the percent of cells in the differential. Each cell ratio was calculated by 
dividing the postoperative cell count by the preoperative cell count; a ratio greater than one 
corresponds to an increase in circulating cells postoperatively, whereas a ratio less than one 
corresponds to a decrease in circulating cells postoperatively.  
 
Results are reported as mean ± SEM. Categorical variables were analyzed using Pearson’s 
Chi-Square or the Fisher exact test. Continuous variables were analyzed using ANOVA. 
Survival data was analyzed using Kaplan-Meier statistics, and the curves were compared 
using the Log Rank (Mantel-Cox) test. The effect of multiple patient risk factors on the 
dependent variable of interest was analyzed by multivariable logistic regression. All tests 
were 2-tailed and p values ≤ 0.05 were considered statistically significant. (Statview 5.0, 







There were a total of 110 lower extremity peripheral bypass surgery cases performed at the 
VA Connecticut Healthcare System between July 2002 and June 2007. A total of 32 cases 
from the initial 110 charts reviewed met the inclusion, but not the exclusion, criteria and 
were the subject of this study.  
 
Three-fourths of our study population (n=24) had baseline critical limb ischemia (CLI; 
Fontaine Stage III-IV), and presented with rest pain, chronic foot ulceration, and/or gangrene 
requiring operative intervention. One-fourth of our study population (n=8) did not present 
with signs of CLI, i.e. had no baseline ischemia, and were designated the control group. Half 
of these patients (n=4) had bypass surgery for exclusion of asymptomatic popliteal aneurysm 
and the other half (n=4) had surgery for relief of intermittent claudication (Fontaine Stage II).  
 
The demographics of these patients are listed in Table 1. The mean age of CLI patients was 
67.6 ± 1.7 years and the mean age of controls was 72.6 ± 5.1 years; there was no significant 
difference in age between the two groups (p=0.242). All of the patients were men, as this 
study was conducted within the VA system (Table 1). 
 
Diabetes (n=10) was more prevalent in the group with CLI as compared to control patients 
(41.7% vs. 0%; p=0.035).  Smoking was also distributed unequally; of the patients who had 
never smoked (n=3) none were in the CLI group (0% of CLI patients vs. 37.5% of controls; 
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p=0.003).  Of the patients who were prior smokers but had quit before the surgery (n=14) 
there was little difference between groups (41.7% of CLI patients vs. 50% of controls); and 
of the patients who were current smokers at the time of the surgery (n=15) the majority were 
in the CLI group (58.3% of CLI patients vs. 12.5% of controls; p=0.003). There was no 
significant difference between the two groups in terms of age, sex, statin therapy, type of 
graft, outflow vessel, or operative extremity (Table 1).   
 
Patients with CLI had increased preoperative monocyte counts compared to controls (0.753 ± 
0.04 vs. 0.516 ± 0.05; p=0.0046) but there was no difference in preoperative lymphocyte 
counts between patients with CLI and controls (1.979 ± 0.14 vs. 1.912 ± 0.22; p=0.814).  
Patients with CLI also had elevated preoperative WBC counts (9.517 ± 0.56 vs. 7.225 ± 1.10; 
p=0.055) and neutrophil counts (6.458 ± 0.53 vs. 4.612 ± 0.93; p=0.092) compared to control 
patients, but these differences were not significant (Table 1). 
 
Outcomes 
Postoperative outcomes are presented in Table 2.  Follow-up was complete in all patients; 
however, the mean follow-up time was slightly shorter in patients with ischemia compared to 
control patients (2.14 years vs. 3.26 years; p=0.042).  Consistent with the study design, all 
deaths and amputations occurred outside of the study time frame, which was defined as the 
time bounded by the dates of the preoperative and postoperative CBC. Death prior to a 
postoperative CBC would exclude the patient due to insufficient data, and amputation would 
exclude the patient due to graft failure and unsuccessful resolution of limb ischemia at the 
time of the postoperative CBC. Deaths (n=9) occurred only in CLI patients (37.5% vs. 0%; 
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p=0.070) and amputations (n=4) also occurred only in CLI patients (16.7% vs. 0%; p=0.550). 
These results are notable but not statistically significant (Table 2). 
 
Thrombosed grafts were grouped by the date of occurrence (within or outside the study time 
frame). Of the patients who had thrombosed grafts within the study time frame (n=4) none 
were in the CLI group (16.7% of CLI patients vs. 0% of controls; p=0.550). After the study 
time frame, the majority of patients who had thrombosed grafts (total n=9) were in the CLI 
group (n=8 or 33.3% of CLI patients vs. n=1 or 12.5% of controls; p=0.386; Table 2). 
 
The survival curves for mortality rate, amputation rate, and thrombosis rate are shown in 
Figure 3. Survival data was analyzed using Kaplan-Meier statistics, and the curves were 
compared using the Log Rank (Mantel-Cox) test. These curves demonstrate the percent of 
patients in the CLI group and the control group who remained free of any given event (death, 
amputation, or thrombosis) over time. Patients dropped out of the analysis either on the date 
of last follow-up or on the date of the index event (Figure 3). 
 
The mortality curve (Figure 3A) shows a significant difference between the groups. All 
deaths (n=9) occurred in CLI patients within three years of the surgery. Approximately 91% 
of the CLI patients were alive at one year, 73% at two years, and 47% at three years. This is 





The amputation curve (Figure 3B) shows no significant difference between groups. All 
amputations (n=4) occurred in CLI patients within two years of the surgery. Approximately 
92% of the CLI patients were intact at one year, and 76% at two years. These results are not 
statistically significant despite the fact that control patients remained 100% intact (p=0.168; 
Figure 3B). 
 
The thrombosis curve (Figure 3C) shows no significant difference between groups. There 
were a total of n=9 thrombotic events; n=8 in the CLI group and n=1 in the control group. 
Thrombosis occurred within two years of the surgery. Approximately 83% of the CLI 
patients had patent grafts at one year, and 58% at two years. All of the control patients had 
patent grafts at one year, and 87.5% were patent at two years. These results are not 
statistically significant (p=0.186; Figure 3C). 
 
Monocyte Counts 
The primary dependent variable of interest was the monocyte ratio, and on univariable 
analysis only two risk factors had a significant effect on this ratio. The univariable analyses 
are summarized in Table 3. This table shows that patients with preoperative CLI had 
decreased monocyte counts after revascularization compared to control patients without 
preoperative CLI (-20% vs. +55%; p=.0003). In addition, diabetic patients also had 
significantly reduced postoperative monocyte counts compared to patients without diabetes  
(-32% vs. +13%; p=0.035). Age greater than or less than 70, statin therapy, smoking status, 
type of graft, outflow vessel, operative extremity, graft status, and mortality had no 




Since mononuclear cells are represented in the peripheral blood by both monocytes and 
lymphocytes, we determined the effect of CLI on both the monocyte and the lymphocyte 
counts. Figure 4 shows the effect of CLI on various peripheral blood cell populations.  In 
patients with CLI, the monocyte ratio decreased significantly after bypass surgery (-20% vs. 
+55%; p=.0003; Figure 4A); however, the lymphocyte ratio was unchanged after 
revascularization in both ischemic and control patients (-10% vs. +1%; p=0.404; Figure 4B).  
In patients with CLI, both the WBC and neutrophil counts were also significantly decreased 
after revascularization (Figure 4). The diminished WBC ratio in patients with CLI (-14% vs. 
+26%; p=0.008; Figure 4C) paralleled the diminished neutrophil ratio (-9% vs. +39%; 
p=0.037; Figure 4D). 
 
To determine the significance of the risk factors identified by univariable analysis, we 
performed multivariable logistic regression to identify which of these risk factors was 
relevant (Table 4). Our results demonstrate that the only factor that independently predicts 
reduced postoperative monocyte count is preoperative CLI (p=0.038). Age, thrombosed graft, 
native graft, smoking status, diabetes, statin therapy, tibial outflow, and mortality do not 






We report two findings consistent with our hypothesis regarding patients with CLI 
undergoing lower extremity peripheral bypass surgery.  First, we report that the preoperative 
monocyte count was elevated in patients with CLI compared to control patients with no 
baseline critical ischemia.  Second, we report that the monocyte count decreased significantly 
after successful revascularization in patients with CLI compared to control patients.  Diabetes 
was also associated with a decreased monocyte count after peripheral bypass surgery; 
however, using multivariable analysis, only CLI independently predicted a decreased 
monocyte count after successful revascularization. 
 
We believe that one of our most significant findings was that the preoperative monocyte 
count was elevated in patients with CLI compared to control patients.  Interestingly, the 
difference was not apparent on the WBC differential, which only lists individual WBC 
populations as percentages of the total WBC count. It is likely that the poor sensitivity for 
differences in the low number of circulating monocytes resulted in a lack of significance 
when percentages were compared. However, normalization to the absolute WBC count 
revealed the greater preoperative absolute number of circulating monocytes in patients with 
CLI (Table 1).  This observation is consistent with our hypothesis that patients with baseline 
CLI secrete paracrine factors such as MCP-1 to stimulate monocyte recruitment from the 
bone marrow, promoting angiogenesis and resolution of ischemia. Notably, monocytes were 
the only WBC component that had significantly different preoperative values when 
comparing patients with CLI to control patients (p=0.0046; Table 1). These results also agree 
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with the report from Nasir and colleagues which demonstrated that elevated circulating 
monocytes were the only WBC fraction that correlated significantly and independently with 
the presence of PAD [86]. Further studies that quantify the severity of ischemia may lead to a 
quantitative correlation between the magnitude of ischemia and the degree of elevation of the 
preoperative monocyte count. 
 
We believe that increased recruitment of monocytes in patients with CLI is intimately related 
to recruitment of EPCs, and that circulating numbers of EPCs correlate inversely with the 
severity of PAD.  We propose that monocytes are recruited in parallel with EPCs, perhaps 
via the same paracrine mechanism.  This possibility is supported by the recent study by 
Sieveking and colleagues, who isolated and defined two different populations of putative 
EPCs, early endothelial progenitor cells (early EPCs) and late outgrowth endothelial cells 
(late OECs) [87].  Early EPCs augment angiogenesis in a paracrine fashion, and have been 
used in therapeutic studies [10,11,50].  In contrast, late OECs form colonies with high 
proliferation rates, and are capable of forming vascular networks in vitro. This EPC and 
monocyte lineage is represented in Figure 2.  It has been proposed that early EPCs are not 
true progenitors of endothelial cells but are actually monocytic cells capable of indirectly 
facilitating angiogenesis in a paracrine fashion, while late OECs are the true EPCs [87].  
 
Thus it is entirely possible that monocytic cells (called “early EPCs” by Sieveking, which 
may not be progenitor cells, despite the nomenclature) stimulate true EPCs (called “late 
OECs” by Sieveking) to respond to ischemia. This possibility correlates with our observation 
that monocytes are increased in patients with ischemia and decreased after resolution of 
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ischemia, since recruitment of EPCs depends on both monocytes and on the severity of 
vascular injury. 
 
Furthermore, in patients with CLI that is severe enough to require peripheral arterial bypass 
surgery, endogenous mechanisms are necessarily insufficient to relieve the ischemia, despite 
elevated levels of MNCs, monocytes, and other paracrine factors. This suggests that the 
monocyte may not be the ultimate effector cell responsible for healing, and reinforces the 
theory that the EPC is the effector cell.  It is possible that elderly and chronically ill patients 
with deficient reserves of EPCs may experience greater increases in monocytes in the setting 
of ischemia due to ineffective EPC recruitment, failure of EPCs to repair vascular injury, or 
other monocyte-EPC interactions. This theory explains the simultaneous existence of two 
findings that seem contradictory: how elevated monocyte counts are present in patients with 
CLI, despite the fact that monocytes participate in vascular healing and resolution of 
ischemia.  
 
The only two demographic variables that were significantly different in ischemic patients 
compared to controls were diabetes and smoking. Diabetes was significantly more prevalent 
in the group with CLI as compared to control patients, and smoking status was also 
distributed unequally, with smokers being at greater risk for more severe disease. For these 





In addition, we also found that monocytes, but not lymphocytes, decreased in patients with 
CLI after successful revascularization with a surgical bypass procedure (Figure 4A and 4B).  
This decrease in monocytes after resolution of ischemia is consistent with our hypothesis that 
monocytes recruit EPCs to promote healing in the setting of ischemia.  These results are also 
consistent with the report from Seidler and colleagues describing the angiogenesis response 
to MCP-1 in ischemic tissue [85]. When resolution of ischemia is achieved, the demand for 
active cell populations that target vessel healing is diminished, decreasing both circulating 
MCP-1 and monocytes.  
 
Importantly, the fact that the lymphocyte ratio did not change postoperatively in either the 
CLI patients or the control patients strongly suggests that it is the monocyte fraction, not the 
lymphocyte fraction, of the mononuclear cell population which is responsive to ischemia. 
 
Notably, we measured the postoperative CBC at a minimum of four months after surgery to 
minimize effects of transient postoperative changes associated with injury, inflammation, and 
stress of the surgical procedure.  Although we were limited to data obtained in a retrospective 
format, and therefore had no control over the dates of test selection, we believe that the 
random sampling of both preoperative and postoperative tests increases the power of 
findings, as there is no test selection bias. 
 
In addition to decreased postoperative monocyte count in patients with CLI, we found that 
the postoperative WBC and neutrophil counts were also diminished in these patients (Figure 
4C and 4D).  Since neutrophils comprise approximately 85% of circulating WBCs, we 
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believe that the diminished postoperative neutrophil count is primarily responsible for the 
diminished WBC count. However, since neutrophils are not mononuclear cells, they cannot 
account for the decrease in monocyte count.  We speculate that the diminished WBC and 
neutrophil counts in patients with successful limb revascularization reflects the resolution of 
preoperative inflammation present in these critically ill patients.  This is consistent with the 
slightly elevated pre-operative WBC counts in patients with CLI, as well as elevated rates of 
smoking and diabetes, compared to control patients (Table 1).  In addition, we believe that 
the increased inflammation in patients with CLI may account for their diminished long-term 
survival (Figure 3A). 
 
One distinct advantage of our control group is that it is composed of patients without baseline 
ischemia who underwent peripheral bypass surgery. This is an unusual patient population, 
since the vast majority of patients who undergo open limb revascularization procedures have 
CLI. The incidental discovery of asymptomatic popliteal aneurysms (n=4 in our control 
group) is also rare. In addition, surgery is not the first line treatment for patients with 
claudication (n=4 in our control group), and is recommended only in patients whose 
claudication interferes significantly with their activities or with their work. The advantage of 
our control group is that it allows comparison of patients with no baseline ischemia to 
patients with critical ischemia before and after the same intervention.  We believe that the 
small increases in monocyte, WBC, and neutrophil ratios in control patients (Figure 4) may 
reflect natural variation in this small number of patients, and additional studies with larger 




A major limitation of this study is the small number of patients. This is primarily due to the 
exclusion of large numbers of patients because they did not have a CBC with differential 
performed as part of their perioperative laboratory studies.  However, enough patients were 
present for us to detect a decrease in postoperative monocyte count.  Since laboratory tests 
may be ordered more frequently for patients admitted to the hospital, selection of an 
asymptomatic control group may be difficult in retrospective studies. In addition, our study 
design selected control patients without limb-threatening graft failure, so our survival data 
(Figure 3) was biased towards patients with better outcomes and is not generalizable to all 
patients with limb revascularization in our institution; on the other hand, selection of patients 
with patent grafts, or only mild graft failure, was necessary to determine whether relief of 
ischemia influenced the monocyte count.  Additional studies that are not retrospective must 
be conducted to confirm the results of this study.  In addition, further studies may allow 
correlation of circulating cytokines and other factors to the level of ischemia and to the 






Our retrospective study suggests that resolution of CLI after surgical revascularization results 
in diminished numbers of circulating monocytes. We believe that this is due to the relief of 
ischemia and a subsequent decrease in the demand for regenerative stem cells recruited from 
the bone marrow. Our theory presupposes that the resolution of ischemia and associated 
inflammation causes a concomitant decrease in circulating cytokines or growth factors, 
resulting in decreased mobilization of stem cells and monocytes from the bone marrow.  
However, the true effector cell remains unclear: of the mononuclear cell fraction, our results 
strongly suggest a role for monocytes rather than lymphocytes. However, as EPCs are 
thought to be a component of the monocyte population, it remains to be determined whether 
the protective and healing effect is due to monocyte activity, EPC activity, or the activity of 
both cell types.  It is reasonable to conclude, however, that circulating monocytes may be a 
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Table 1: Demographic  Variables
Variable Total Number Percent of Total Control Control (%) Ischemic Ischemic (%) P value
Total patients 32         8 24
Age (years) 68.9 ± 1.8 - 72.6  ±  5.1 - 67.6  ±  1.7 - 0.2423
Sex
     Male 32        100.0% 8 100.0% 24 100.0% >0.9999
     Female 0        0.0% 0 0.0% 0 0.0%
Diabetes   
     No 22        68.8% 8 100.0% 14 58.3% 0.0353
     Yes 10        31.3% 0 0.0% 10 41.7%
Statin Therapy   
     No 12        37.5% 3 37.5% 9 37.5% > 0.9999
     Yes 20        62.5% 5 62.5% 15 62.5%
Smoking Status   
     Never a Smoker 3        9.4% 3 37.5% 0 0.0% 0.0028
     Prior Smoker 14        43.8% 4 50.0% 10 41.7%
     Current Smoker 15        46.9% 1 12.5% 14 58.3%
Type of Graft   
     Native Vein 19        59.4% 4 50.0% 15 62.5% 0.6838
     Prosthetic 13        40.6% 4 50.0% 9 37.5%
Outflow Vessel   
     AK Popliteal 10        31.3% 4 50.0% 6 25.0% 0.1091
     BK Popliteal 13        40.6% 4 50.0% 9 37.5%
     Tibial 9        28.1% 0 0.0% 9 37.5%
Operative Extremity   
     Left 10        31.3% 1 12.5% 9 37.5% 0.3803
     Right 22        68.8% 7 87.5% 15 62.5%
7.225 ± 1.10 9.517 ± 0.56 0.0554
1.912 ± 0.22 1.979 ± 0.14 0.8143
4.612 ± 0.93 6.458 ± 0.53 0.0923
0.516 ± 0.05 0.753 ± 0.04 0.0046
0.147 ± 0.03 0.254 ± 0.05 0.2627
0.032 ± 0.01 0.063 ± 0.01 0.1902     Preoperative Basophil Count
     Preoperative Lymphocyte Count
     Preoperative Neutrophil Count
     Preoperative Monocyte Count
     Preoperative Eosinophil Count







Table 2: Outcome Variables
Variable Total Number Percent of Total Control Control (%) Ischemic Ischemic (%) P value
Total patients 32         8 24
Mean Follow-Up Time (years) 2.42 3.26 2.14 0.0421
Mortality:
     Alive 23        71.9% 8 100.0% 15 62.5% 0.0699
     Dead 9        28.1% 0 0.0% 9 37.5%
Limb Status:
     Intact 28        87.5% 8 100.0% 20 83.3% 0.5497
     AKA or BKA 4        12.5% 0 0.0% 4 16.7%
Graft Status:
     Within study time frame
          Patent 28        87.5% 8 100.0% 20 83.3% 0.5497
          Thrombosed 4        12.5% 0 0.0% 4 16.7%
     Through Follow-Up
          Patent 23        71.9% 7 87.5% 16 66.7% 0.3858




Table 3: Univariable Analysis for
Factors Affecting Monocyte Ratio
Variable Risk Factor Mean Monocyte Ratio P-value
Age (years)         <  70 1.077 0.3726
70 0.898
Preoperative CLI No 1.554 0.0003
Yes 0.799
Diabetes No 1.127 0.0348
Yes 0.682
Statin Therapy No 0.952 0.7858
Yes 1.009
Smoking Status Never a Smoker 1.182 0.5655
Prior Smoker 1.063
Current Smoker 0.878
Type of Graft Native Vein 0.940 0.5693
Prosthetic 1.057
Outflow Vessel AK Popliteal 1.192 0.0740
BK Popliteal 1.071
Tibial 0.641
Operative Extremity Left 0.996 0.9552
Right 0.984
Graft Status Patent 1.002 0.7126
     (within study time frame) Thrombosed 0.889
Mortality Alive 1.088 0.1055





Table 4: Multivariable Logistic
Regression Analysis
∞
Variable P-Value Exp (Coef) 95% Lower 95% Upper
Age 0.5506 1.046 0.903 1.211
Thrombosed Graft 0.1212 0.021 1.62E-04 2.775
Native Graft 0.2664 0.186 0.01 3.619
Preoperative CLI 0.0377 91.883 1.291 6538
Smoking Status 0.9155 1.245 0.022 71.239
Diabetes 0.6373 0.423 0.012 15.169
Statin Therapy 0.5023 0.348 0.016 7.596
Tibial Outflow 0.9962 4.77E+08 0  








Figure 1: Endothelial Cell Derivation Diagram  
Multiple cell types are known to give rise to endothelial cells. Bold arrows show the pathway most 
commonly cited. Adapted from Urbich [12] and colleagues. VE cadeherin = vascular endothelial 
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Figure 2: EPC and Monocyte Lineage Diagram  
Bold arrows show the pathways most commonly cited. Dashed arrow shows the pathway for 
paracrine stimulation. Adapted from Urbich [12] and Shantsila [89]. VE cadeherin = vascular 
endothelial cadherin; VEGF-R2 = vascular endothelial growth factor receptor 2; vWF = von 
Willebrand factor; early “EPC” = early endothelial progenitor cell, found to be a monocyte, not a 
progenitor cell, by Sieveking and colleagues [87]; question mark on early “EPC” monocyte cell 
membrane suggests specific markers are unknown; late outgrowth endothelial cell, found to be a true 
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Figure 3: Survival Curves
Thrombosis Rate and Patent Proportions

























Figure 3: Survival Curves 
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Figure 4: Effect of Critical Limb Ischemia






Figure 4: Effect of Critical Limb Ischemia on Peripheral 
Blood Cell Populations 
